2,645 results match your criteria Expert opinion on biological therapy[Journal]


Towards personalized treatment in atopic dermatitis.

Expert Opin Biol Ther 2019 Feb 15. Epub 2019 Feb 15.

a National Expertise Center for Atopic Dermatitis. Department of Dermatology and Allergology , University Medical Center Utrecht , The Netherlands .

Introduction: For many years, oral immunosuppressive drugs such as cyclosporine A, azathioprine, mycophenolic acid and methotrexate were the only treatment options, in addition to topical treatment, in patients with severe atopic dermatitis (AD). Dupilumab, a monoclonal antibody targeting the IL-4 receptor alpha, is the first antibody-based treatment commercially available for the treatment of AD. In the near future, more antibody-based treatments and small molecules will become available in the treatment of severe AD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1583204DOI Listing
February 2019

A comprehensive review of hormonal and biological therapies for endometriosis: latest developments.

Expert Opin Biol Ther 2019 Feb 14. Epub 2019 Feb 14.

a Academic Unit of Obstetrics and Gynecology , Ospedale Policlinico San Martino , Largo R. Benzi 10, 16132 Genoa , Italy.

Introduction: Endometriosis is a chronic benign estrogen dependent disease characterized by the presence of endometriotic glands and stroma outside the uterine cavity. Although combined hormonal contraceptives and progestins, currently available first-line treatments for endometriosis, are efficacious and well tolerated for treating disease-related pain, some women experience partial or no improvement of pain or its recurrence is frequent after discontinuation of the therapies. For these reasons, new drugs are under investigation for the treatment of endometriosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1581761DOI Listing
February 2019

Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancy.

Expert Opin Biol Ther 2019 Feb 14. Epub 2019 Feb 14.

a Institute for Health Science Research Germans Trias i Pujol (IGTP) , Badalona , Spain.

Introduction: Biological therapies, with immunotherapy leading the field, have arisen as one of the quickest expanding areas of research for cancer treatment in the last few years. The clear benefits for patients are undeniable, satisfying the long-awaited necessity of a target-specific therapy. However, its full potential remains still unexploited due to a lack of response in a majority of patients and pending reliable biomarkers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1582635DOI Listing
February 2019
1 Read

Advances in stem cell therapy for male stress urinary incontinence.

Expert Opin Biol Ther 2019 Feb 1:1-8. Epub 2019 Feb 1.

a Department of Surgery, Division of Urology , San Paolo Hospital , Savona , Italy.

Introduction: Among the several options that have been proposed in recent years for the management of male stress urinary incontinence (SUI), stem cell therapy represents a new frontier in treatment. The aim of this paper is to update the current status of stem cell therapy in animal and human studies for the management of iatrogenic male SUI. Areas covered: A literature review was conducted based on MEDLINE/PubMed searches for English articles using a combination of the following keywords: stem cell therapy, urinary incontinence, prostatectomy, regenerative medicine, mesenchymal stem cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1578343DOI Listing
February 2019

Advances in stem cell treatment for sciatic nerve injury.

Expert Opin Biol Ther 2019 Jan 31:1-11. Epub 2019 Jan 31.

a Neuroscience Research Center, Faculty of Medicine , Guilan University of Medical Sciences , Rasht , Iran.

Introduction: The sciatic nerve is one of the peripheral nerves that is most prone to injuries. After injury, the connection between the nervous system and the distal organs is disrupted, and delayed treatment results in distal organ atrophy and total disability. Regardless of great advances in the fields of neurosurgery, biological sciences, and regenerative medicine, total functional recovery is yet to be achieved. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1576630DOI Listing
January 2019

GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods.

Expert Opin Biol Ther 2019 Jan 30:1-9. Epub 2019 Jan 30.

a Global Clinical Development, Biopharmaceuticals , Hexal AG (A Sandoz company) , Holzkirchen , Germany.

Background: To compare the pharmacokinetics of Sandoz biosimilar adalimumab (GP2017) with reference adalimumab (Humira) in healthy volunteers (PK similarity study) and to compare the pharmacokinetics of GP2017 administered by autoinjector (AI) or prefilled syringe (PFS; delivery study).

Methods: Healthy male subjects were randomized to receive a single 40 mg subcutaneous injection of GP2017, US-licensed or EU-authorized reference adalimumab (US/EU-Humira; PK similarity study) or a single 40 mg subcutaneous injection of GP2017 via AI or PFS (delivery study). Pharmacokinetics, safety, and immunogenicity were assessed over 72 days post-injection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1571580DOI Listing
January 2019

Rational and clinical development of the anti-MAdCAM monoclonal antibody for the treatment of IBD.

Expert Opin Biol Ther 2019 Jan 29:1-6. Epub 2019 Jan 29.

a Inflammatory Bowel Disease Center and Amsterdam Gastroenterology and Metabolism , Amsterdam UMC, University of Amsterdam , Amsterdam , The Netherlands.

Introduction: Mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expression in gut-associated lymphoid tissue is upregulated in patients with inflammatory bowel disease (IBD). Blocking adhesion molecules and thereby inhibiting migration of lymphocytes into sites of inflammation in the gut is an attractive new treatment target in drug development for IBD. Areas covered: This review discusses the preclinical and clinical experience on SHP647 (previously called PF-00547659 and PF-00547,659), a fully human IgG2K monoclonal antibody that binds to MAdCAM-1 to selectively reduce lymphocyte homing to the intestinal tract. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1576631DOI Listing
January 2019
1 Read

Complement inhibition as a therapeutic strategy in retinal disorders.

Expert Opin Biol Ther 2019 Jan 26:1-8. Epub 2019 Jan 26.

d Retinal Consultants of Arizona, Phoenix, Arizona; USC Roski Eye Institute, Keck School of Medicine , University of Southern California , Los Angeles , CA , USA.

Introduction: Dry age-related macular degeneration (AMD) and Stargardt Macular Dystrophy (STGD1) result in vision loss due to progressive atrophy of the macula and lack of effective treatments. Numerous studies have implicated complement-associated inflammation as a contributor to both diseases. Areas covered: The complement factor D inhibitor, lampalizumab, failed to halt geographic atrophy (GA) progression in phase 3 studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1575358DOI Listing
January 2019
3.743 Impact Factor

Disease modeling of cardiac arrhythmias using human induced pluripotent stem cells.

Expert Opin Biol Ther 2019 Jan 25:1-21. Epub 2019 Jan 25.

a Division of Cardiology, Department of Medicine , University of Ottawa Heart Institute , Ottawa , Canada.

Introduction: Inherited arrhythmias are an uncommon, but malignant family of cardiac diseases that result from genetic abnormalities in the ion channels and/or structural proteins within cardiomyocytes. Given the inherent differences between species and the limited reproducibility of in vitro heterologous cell models, progress in understanding the mechanisms underlying these malignant diseases has always languished far behind the clinical science and need. The ability to study human induced pluripotent stem cells (iPSCs) derived cardiomyocytes promises to change this paradigm as patient cells have the potential to become testing platforms for disease phenotyping or therapeutic discovery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1575359DOI Listing
January 2019
2 Reads

Current and emerging biologic and small molecule therapies for atopic dermatitis.

Expert Opin Biol Ther 2019 Jan 23:1-14. Epub 2019 Jan 23.

a Department of Dermatology, Laboratory of Inflammatory Skin Diseases , Icahn School of Medicine at Mount Sinai , New York , NY , USA.

Introduction: Atopic dermatitis (AD) is the most common inflammatory skin disease, yet until recently there were no safe systemic therapies approved for the long-term management of AD in adult patients. A deeper understanding of disease pathogenesis and identification of molecular and cellular changes has resulted in a rapidly evolving pipeline of therapeutics that holds promise for safer long-term control. Areas covered: In this review, we highlight the growing arsenal of biologic and small molecule antagonists that target pathways implicated in AD pathogenesis. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1573422DOI Listing
January 2019
3 Reads

Development of new agents for peripheral T-cell lymphoma.

Expert Opin Biol Ther 2019 Mar 29;19(3):197-209. Epub 2019 Jan 29.

a Department of Hematology , National Cancer Center Hospital , Tokyo , Japan.

Introduction: Peripheral T-cell lymphoma (PTCL) is a relatively rare, heterogeneous group of mature T-cell neoplasms generally associated with poor prognosis, partly because of refractoriness against conventional cytotoxic chemotherapies. To improve the outcome of patients with PTCL, the clinical development of several novel agents is currently under investigation. Areas covered: Since the first approval of pralatrexate (dihydrofolate reductase inhibitor) by the US Food and Drug Administration, belinostat, romidepsin (histone deacetylase inhibitors), and brentuximab vedotin (anti-CD30 antibody-drug conjugate) have been approved in the US, and many other countries. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1572746DOI Listing
March 2019
13 Reads

Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer.

Expert Opin Biol Ther 2019 Mar 25;19(3):225-232. Epub 2019 Jan 25.

a Thoracic Oncology Department , H. Lee Moffitt Cancer Center and Research Institute , Tampa , FL , USA.

Introduction: Immunotherapy, either as monotherapy or in combination with chemotherapy, has demonstrated superior efficacy to chemotherapy alone in the frontline setting. To date, there has been no randomized study comparing immunotherapy alone with chemo-immunotherapy. Areas Covered: This paper reviews the immunobiological rationale for combining chemotherapy with checkpoint inhibitors as well as the data from recent phase-3 studies to understand the risks and benefits associated with either therapeutic approach for diverse patient populations. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1571036DOI Listing
March 2019
3 Reads

An updated review of adipose derived-mesenchymal stem cells and their applications in musculoskeletal disorders.

Expert Opin Biol Ther 2019 Mar 25;19(3):233-248. Epub 2019 Jan 25.

a Department of Anatomy and Embryology, Faculty of Medicine , University of Granada , Granada , Spain.

Introduction: Adipose-derived mesenchymal stem cells (ASCs) represent a new therapeutic strategy in biomedicine with many potential applications, especially in musculoskeletal disorders. Preclinical and clinical studies based on the administration of ASCs support their efficacy in bone regeneration, joint repair, tendon injury and skeletal muscle alterations. Many of these novel treatments may improve patients' quality of life and prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1563069DOI Listing
March 2019
2 Reads

CheckMate 141 trial: all that glitters is not gold.

Expert Opin Biol Ther 2019 Mar 21;19(3):169-171. Epub 2019 Jan 21.

e Department of Precision Medicine , University of Campania "L. Vanvitelli" , Naples and Biogem , Avellino Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1570498DOI Listing

B cell depletion in the treatment of multiple sclerosis.

Expert Opin Biol Ther 2019 Mar 23;19(3):261-271. Epub 2019 Jan 23.

c Department of Neurology , Akershus University Hospital , Lørenskog , Norway.

Introduction: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. The latest development of B-cell depletion by anti-CD20 monoclonal antibodies has been a large step forward in the treatment of this devastating disease. Areas covered: In this manuscript, we review mechanisms of action, efficacy, safety, and tolerance of anti-CD20 therapies for MS, including rituximab, ocrelizumab, and ofatumumab. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1568407DOI Listing
March 2019
5 Reads

The role of healthcare providers in accompanying biosimilars in inflammatory bowel diseases.

Expert Opin Biol Ther 2019 Jan 8. Epub 2019 Jan 8.

a IBD Unit, Presidio Columbus , Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore , Rome.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1566455DOI Listing
January 2019
2 Reads

Etanercept biosimilar SB-4.

Expert Opin Biol Ther 2019 Mar 11;19(3):173-179. Epub 2019 Jan 11.

a Rheumatology Clinic, Department of Internal Medicine, Medical School , University of Ioannina , Ioannina , Greece.

Introduction: Biosimilars are highly similar molecules to other biological medicines that have already been authorized for use. Etanercept (ETN) was the first anti-tumor necrosis factor inhibitor (TNFi) approved by the Food and Drug Administration for the treatment of moderate to severe rheumatoid arthritis (RA) in November 1998 and in February 2000 by the European Medicines Agency. Twenty years later, the first ETN biosimilar has come of age. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1566456DOI Listing
March 2019
6 Reads
3.743 Impact Factor

Intra-arterial administration of cell-based biological agents for ischemic stroke therapy.

Expert Opin Biol Ther 2019 Mar 21;19(3):249-259. Epub 2019 Jan 21.

a 2nd Department of Radiology, Division of Interventional Radiology, School of Medicine , National and Kapodistrian University of Athens, Attikon University Hospital , Athens , Greece.

Introduction: Ischemic stroke is becoming a primary cause of disability and death worldwide. To date, therapeutic options remain limited focusing on mechanical thrombolysis or administration of thrombolytic agents. However, these therapies do not promote neuroprotection and neuro-restoration of the ischemic area of the brain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1566454DOI Listing
March 2019
2 Reads

MDA-7/interleukin 24 (IL-24) in tumor gene therapy: application of tumor penetrating/homing peptides for improvement of the effects.

Expert Opin Biol Ther 2019 Mar 21;19(3):211-223. Epub 2019 Jan 21.

c Bacteriology and Virology Department, School of Medicine , Shiraz University of Medical Sciences , Shiraz , Iran.

Introduction: MDA-7/Interleukin-24 (IL-24), as a pleiotropic cytokine, exhibits a specific tumor suppression property that has attracted a great deal of attention. While its anti-tumor induction is mostly attributed to endogenous gene expression, attachment of secreted MDA-7/IL-24 to cognate receptors also triggers the death of cancerous cell via different pathways. Therefore, precise targeting of secreted MDA-7/IL-24 to tumor cells would render it more efficacy and specificity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1566453DOI Listing
March 2019
2 Reads

Biosimilars of adalimumab: the upcoming challenge in IBD.

Expert Opin Biol Ther 2019 Jan 2. Epub 2019 Jan 2.

a IBD Center, Department of Gastroenterology , Humanitas Clinical and Research Institute , Rozzano, Milan , Italy.

Introduction Biosimilars represent great potential in cost saving and re-investment opportunities in healthcare and allow patients greater access to effective mAbs. Infliximab biosimilars are successfully used in all indications for whom the reference product (RP) was approved. Areas covered In late 2018, adalimumab biosimilars will also be available in patients with inflammatory bowel disease (IBD). Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1564033DOI Listing
January 2019
6 Reads

Characteristics of biological therapy in pediatric patients with Crohn's disease.

Expert Opin Biol Ther 2019 Mar 11;19(3):181-196. Epub 2019 Jan 11.

d Pediatric Institute-Clinic , University of Debrecen , Debrecen , Hungary.

Introduction: At present, there is a significant amount of data related to biologics used in pediatric patients with Crohn's disease. This review characterizes the different biological drugs administered in this population. Areas covered: Biological therapy of CD, focusing on children, is summarized in this review. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1564034DOI Listing
March 2019
1 Read

Direct cellular reprogramming and inner ear regeneration.

Expert Opin Biol Ther 2018 Dec 25. Epub 2018 Dec 25.

a Department of Otolaryngology-Head and Neck Surgery , Stanford University School of Medicine , Stanford , CA , 94305 , USA .

Introduction: Sound is integral to communication and connects us to the world through speech and music. Cochlear hair cells are essential for converting sounds into neural impulses. However, these cells are highly susceptible to damage from an array of factors, resulting in degeneration and ultimately irreversible hearing loss in humans. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1564035DOI Listing
December 2018

The rise of human stem cell-derived natural killer cells for cancer immunotherapy.

Expert Opin Biol Ther 2018 Dec 24:1-8. Epub 2018 Dec 24.

b Department of Medicine, Division of Regenerative Medicine , University of California San Diego , San Diego , CA , USA.

Introduction: Natural killer (NK) cell therapy has been proven to be safe and clinically effective for the treatment of multiple cancers, in particular blood cancers. Most of the clinical trials use primary NK cells from peripheral blood or umbilical cord blood, or NK-92 cells. Each cell source is confined by limitations, such as donor dependence, low persistence in vivo, and its difficulty to genetically modify. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1559293DOI Listing
December 2018

Are hair follicle stem cells promising candidates for wound healing?

Expert Opin Biol Ther 2018 Dec 21. Epub 2018 Dec 21.

a Wound Healing and Cell Biology Laboratory, Institute of Basic Medicine Science, College of Life Science , Chinese PLA General Hospital , 28 Fuxing Road, Beijing , 100853 , People's Republic of China.

Introduction:With the continued focus on in-depth investigations of hair follicle stem cells (HFSCs), the role of HFSCs in wound healing has attracted increasing attention from researchers. This review may afford meaningful implications for HFSC treatment of wounds. Areas covered: We present the properties of HFSCs, analyze the possibility of HFSCs in wound healing, and sum up the recent studies into wound repair with HFSCs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1559290DOI Listing
December 2018
2 Reads

Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn's disease: pharmacological and clinical implications.

Expert Opin Biol Ther 2019 Feb 2;19(2):79-88. Epub 2019 Jan 2.

d Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine , University of Pisa , Pisa , Italy.

Introduction: Crohn's disease (CD) is an inflammatory bowel disease of unknown etiology. However, increasing evidence suggests Mycobacterium avium subspecies paratuberculosis (MAP) as a putative causative agent: 1) MAP is the etiological agent of Johne's disease, a granulomatous enteritis affecting ruminants, which shares clinical and pathological features with CD; 2) MAP has been detected in tissues and blood samples from CD patients; 3) case reports have documented a favorable therapeutic response to anti-MAP antibiotics. Area covered: This review provides an appraisal of current information on MAP characteristics, diagnostic methodologies and emerging drug treatments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1561852DOI Listing
February 2019
8 Reads
3.743 Impact Factor

Bioequivalence studies with anti-TNF biosimilars.

Expert Opin Biol Ther 2018 Dec 21. Epub 2018 Dec 21.

c Departamento de Medicina, Facultad de Medicina. Digestive Diseases Service . Hospital Clínico Universitario "Lozano Blesa" ; IIS Aragón; CIBEREHD , Zaragoza , Spain .

Introduction: Biosimilars, as defined by the European Medicines Agency, have been used in Europe since 2006. The landscape was considerably expanded when the first biosimilar of a monoclonal was approved and introduced in the European market. CT-P13 was developed by Celltrion as an infliximab biosimilar in 2013, not without controversy. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1561851DOI Listing
December 2018
3 Reads

Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies.

Expert Opin Biol Ther 2018 Dec 20. Epub 2018 Dec 20.

a Division of Rheumatology, Department of Medicine , Karolinska Institutet , Stockholm , Sweden.

Objectives: Development of therapies for systemic lupus erythematosus (SLE) has in part been limited by the lack of suitable outcome measures in clinical trials. In the present post-hoc analysis of two clinical trials of belimumab, we investigated two potential outcomes, the Lupus Low Disease Activity State (LLDAS) and clinical SLE disease activity index 2000 (cSLEDAI-2K) zero, in relation to SLE responder index 4 (SRI-4).

Methods: A total of 1684 SLE patients from the BLISS-52 (n=865) and BLISS-76 (n=819) trials were surveyed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1561856DOI Listing
December 2018
1 Read

Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease.

Expert Opin Biol Ther 2018 Dec 20. Epub 2018 Dec 20.

b Internal Medicine Unit, ''Villa Sofia-Cervello'' Hospital , Via Trabucco 180, 90146 Palermo , Italy .

Introduction: Blockers of IL-12/23, as well as specific blockers of IL-23, have been investigated as options for medical therapy in inflammatory bowel disease. These biological agents include ustekinumab - the first agent of this pharmacological class which has shown clinical efficacy in psoriasis, psoriatic arthritis, and moderate-to-severe Crohn's disease (CD) - and other monoclonal antibodies under investigation, including brazikumab, risankizumab, mirikizumab, and guselkumab. Areas covered: This review will focus on the rationale of the blockade of IL-12/23 axis in CD, efficacy and safety data of ustekinumab derived from randomized controlled trials and real-life observational studies, and the preliminary data of the highly promising selective IL-23 inhibitors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1561850DOI Listing
December 2018
1 Read

Promoting vascularization for tissue engineering constructs: current strategies focusing on HIF-regulating scaffolds.

Expert Opin Biol Ther 2018 Dec 20. Epub 2018 Dec 20.

a Experimental Renal and Cardiovascular Research, Department of Nephropathology , Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) , 91054 Erlangen , Germany.

Introduction: Vascularization remains one of the greatest yet unmet challenges in tissue engineering. When engineered tissues are scaled up to therapeutically relevant dimensions, their demand of oxygen and nutrients can no longer be met by diffusion. Thus, there is a need for perfusable vascular structures. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1561855DOI Listing
December 2018
6 Reads

Biological therapy of autoimmune blistering diseases.

Authors:
Mauro Alaibac

Expert Opin Biol Ther 2019 Feb 18;19(2):149-156. Epub 2018 Dec 18.

a Unit of Dermatology , University of Padua , Padua , Italy.

Introduction: Autoimmune blistering skin diseases are a group of disorders subdivided according to the location of blister formation: intraepidermal blistering in the pemphigus group and subepidermal in the pemphigoid group. These conditions are clinically heterogeneous and are treated with systemic corticosteroids and/or other forms of immunosuppression on the basis of clinical subtype and disease severity. These approaches may not be effective for the induction and maintenance of clinical response or need to be stopped because of intolerable side effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1559291DOI Listing
February 2019
1 Read

Bevacizumab in refractory higher-grade and atypical meningioma: the current state of affairs.

Expert Opin Biol Ther 2018 Dec 17:1-6. Epub 2018 Dec 17.

e Department of Radiology and Imaging , State University of Medicine and Pharmacy "Nicolae Testemitanu" , Chisinau , Moldova.

Introduction: Historically, systemic agents had shown limited efficacy in meningioma, at the expense of significant pharmacologic and/or financial toxicity. As meningiomas are highly vascularized, they might derive benefit from antiangiogenic therapy. Areas covered: This review summarizes the literature regarding bevacizumab pharmacology, safety and efficacy in patients with refractory meningioma. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1559292DOI Listing
December 2018
6 Reads

Mechanism of action of the trastuzumab biosimilar CT-P6.

Expert Opin Biol Ther 2018 Dec 13:1-11. Epub 2018 Dec 13.

a Biotechnology Research Institute, Celltrion Inc , Incheon , Republic of Korea.

Objectives: Therapeutic monoclonal antibody biosimilars are expected to help reduce the sizeable economic burden of targeted treatments. Trastuzumab (Herceptin®), a recombinant humanized monoclonal antibody that binds to the extracellular domain of HER2, is approved for use in HER2-overexpressing breast cancer (in both the adjuvant and metastatic settings) and HER2-positive gastric cancer. CT-P6 (Herzuma®) is a biosimilar of trastuzumab, designed to bind with high affinity and specificity to the same HER2 epitope as the reference product. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1554052DOI Listing
December 2018
10 Reads

The value of immunotherapy in head and neck cancer.

Expert Opin Biol Ther 2019 Jan 20;19(1):35-43. Epub 2018 Dec 20.

d Marlene and Stewart Greenebaum Comprehensive Cancer Center , University of Maryland School of Medicine , Baltimore , Maryland , USA.

Introduction: Head and neck squamous cell carcinomas (HNSCC) previously had limited treatment options once patients had progressed on systemic chemotherapy. With recent advances, immunotherapy now plays an important role in the treatment of advanced disease with improved outcomes as compared to cytotoxic chemotherapy. Areas covered: This article reviews the effects of the immune system and how it influences the development and response to HNSCC therapy. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1556637DOI Listing
January 2019
10 Reads

A vaccine against Alzheimer`s disease: anything left but faith?

Expert Opin Biol Ther 2019 Jan 17;19(1):73-78. Epub 2018 Dec 17.

a RIA Immunology, Department of BioMedical Research , University of Bern , Bern , Switzerland.

Introduction: Alzheimer's disease looms as a profound and growing threat to future human health. The disease is thought to be primarily driven by aberrant proteolysis of the amyloid precursor protein (APP) and amyloid beta (Aβ) plaque deposition. Areas covered: We provide an overview of the molecular pathology that leads to an increase in Aβ peptide accumulation, of the mechanism of action for antibody mediated therapies and of the therapeutic vaccines that target Aβ under development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1554646DOI Listing
January 2019

Application of amniotic membrane in reconstructive urology; the promising biomaterial worth further investigation.

Expert Opin Biol Ther 2018 Dec 6. Epub 2018 Dec 6.

e Chair of Urology, Department of Regenerative Medicine, Collegium Medicum , Nicolaus Copernicus University , Bydgoszcz , Poland ;

Introduction: In reconstructive urology, autologous tissues such as intestinal segments, skin, and oral mucosa are used. Due to their limitations, reconstructive urologists are waiting for a novel material, which would be suitable for urinary tract wall replacement. Human amniotic membrane (AM) is a naturally derived biomaterial with a capacity to support reepithelization and inhibit scar formation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1556255DOI Listing
December 2018
4 Reads

The role of biologics in the treatment of giant cell arteritis.

Expert Opin Biol Ther 2018 Dec 4. Epub 2018 Dec 4.

d Rheumatology Division , Hospital de La Princesa, IIS-Princesa, Universidad Autónoma de Madrid (UAM) , Madrid , Spain .

Introduction: Giant cell arteritis is a vasculitis of large and middle-sized arteries that affects individuals older than 50 years. Although glucocorticoids remain the mainstay in the treatment of this vasculitis, other drugs are often required to achieve clinical remission and allow glucocorticoid discontinuation. Areas covered: The review summarizes the main biologic therapies used for the managements of GCA. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1556256DOI Listing
December 2018
9 Reads

Anti-IL17 therapies for psoriasis.

Expert Opin Biol Ther 2018 Nov 30. Epub 2018 Nov 30.

a Division of Dermatology , Baylor Scott and White - Dallas , Dallas , TX , USA.

Introduction: Interleukin-17 (IL-17) is a proinflammatory cytokine considered to play a significant role in the immunopathogenesis of plaque psoriasis. As a result, focus in clinical trials has undergone a shift towards disease specific targets, with the goals of more effective treatment and reduction in the incidence of serious adverse events. Areas Covered: Two monoclonal antibodies targeting IL-17A (secukinumab, ixekizumab) and one against the IL-17 receptor (brodalumab) are approved for the treatment of moderate-to-severe plaque psoriasis. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1555235DOI Listing
November 2018
21 Reads

Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis.

Expert Opin Biol Ther 2019 Jan 7;19(1):55-64. Epub 2018 Dec 7.

a Department of Rheumatology , CHRU de BESANCON, University Teaching Hospital , Besançon , France.

Introduction: Ankylosing spondylitis is the prototype of spondyloarthritis, a chronic inflammatory disease involving mainly the axial skeleton. The treatment strategy was, until now, restricted to NSAIDs and anti-TNF agents. Targeting Interleukin 17 is an emerging option with a currently available biologic agent, secukinumab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1554053DOI Listing
January 2019
14 Reads

Stand Alone or Join Forces? Stem Cell Therapy for Stroke.

Expert Opin Biol Ther 2018 Nov 27. Epub 2018 Nov 27.

a Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair , University of South Florida Morsani College of Medicine , Tampa , FL 33612 , USA.

Introduction: Stroke is a major cause of mortality and disability with a narrow therapeutic window after onset. Stem cell therapy may enhance the functional and neurological outcome after stroke. Areas Covered: Regenerative medicine via stem cells stands as a novel approach for stroke therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1551872DOI Listing
November 2018

Risankizumab for the treatment of moderate to severe psoriasis.

Expert Opin Biol Ther 2018 Nov 21:1-8. Epub 2018 Nov 21.

a Dermatology Unit, Department of Clinical and Experimental Medicine , University of Pisa , Pisa , Italy.

Introduction: Psoriasis is a chronic inflammatory skin disorder pathogenically mediated by multiple cytokines, including interleukin (IL)-23, IL-17, and TNF. An emerging class of therapeutics that selectively blocks IL-23 has been developed. Among these new agents, risankizumab is now being investigated in phase III clinical trials, and the preliminary data are promising in inducing an excellent clinical response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1551354DOI Listing
November 2018
11 Reads

Respiratory syncytial virus vaccine: where are we now and what comes next?

Expert Opin Biol Ther 2018 Dec 14;18(12):1247-1256. Epub 2018 Nov 14.

a Department of Pediatrics, Children's Medical Center , NYU Winthrop Hospital , Mineola , NY , USA.

Introduction: Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection in infants and elderly and to date, there is no safe or effective vaccine against RSV. Areas Covered: This review provides a roadmap to RSV vaccine development. It is a journey spanning over more than half a century from the initial disappointment with inactivated formalin vaccine to the current advancements in vaccine technology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2018.1544239DOI Listing
December 2018

Cell secretome based approaches in Parkinson's disease regenerative medicine.

Expert Opin Biol Ther 2018 Dec 20;18(12):1235-1245. Epub 2018 Nov 20.

a Life and Health Sciences Research Institute (ICVS), School of Medicine , University of Minho , Braga , Portugal.

Introduction: The available therapeutic strategies for Parkinson's disease (PD) rely only on the amelioration of the symptomatology of the disease, lacking neuroprotection or neuroregeneration capacities. Therefore, the development of disease modifying strategies is extremely important for the management of PD in the long term. Areas covered: In this review, the authors provide an overview of the current therapeutic approaches for PD and the emerging use of stem cell transplantation as an alternative. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2018.1546840DOI Listing
December 2018

Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies.

Expert Opin Biol Ther 2018 Dec 14;18(12):1257-1270. Epub 2018 Nov 14.

a John van Geest Centre for Brain Repair, Department of Clinical Neurosciences , University of Cambridge , Cambridge , UK.

Introduction: Diabetic retinopathy (DR) is the leading cause of vision loss in the working age population of the developed world. DR encompasses a complex pathology, and one that is reflected in the variety of currently available treatments, which include laser photocoagulation, glucocorticoids, vitrectomy and agents which neutralize vascular endothelial growth factor (VEGF). Whilst these options demonstrate modest clinical benefits, none is yet to fully attenuate clinical progression or reverse damage to the retina. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2018.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2018.1545836DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299358PMC
December 2018
13 Reads

CD38 as an immunotherapeutic target in multiple myeloma.

Expert Opin Biol Ther 2018 Dec 13;18(12):1209-1221. Epub 2018 Nov 13.

a Myeloma Unit, Division of Hematology , University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino , Torino , Italy.

Introduction: Multiple myeloma (MM) is a currently incurable hematologic tumor with heterogeneous clinical behavior and prognosis. During the last years, survival improved due to a better understanding of MM biology and the development of novel drugs, although it still remains unsatisfactory in many cases: new drugs and treatment strategies are needed. CD38 is uniformly expressed at high levels on MM cells and, to a lesser extent, on the surface of normal hematopoietic and non-hematopoietic cells, making this molecule an interesting target for immunotherapeutic approaches. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2018.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2018.1544240DOI Listing
December 2018
17 Reads

Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?

Expert Opin Biol Ther 2018 Dec;18(12):1199-1207

b Department of Cutaneous Oncology and Sarcoma , Moffitt Cancer Center , Tampa , FL , USA.

Introduction: Melanoma treatments have evolved rapidly in the past decade and have included the use of intratumoral injections of engineered oncolytic viruses. One such oncolytic virus is talimogene laherparepvec (T-VEC), which is the first approved therapy of its kind for use in recurrent, unresectable stage IIIB-IVM1a melanoma. Additional oncolytic viruses and their uses in combination with other interventions are currently under investigation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2018.1544614DOI Listing
December 2018
10 Reads

Grasping at straws: the failure of solanezumab to modify mild Alzheimer's disease.

Expert Opin Biol Ther 2018 Dec 9;18(12):1189-1192. Epub 2018 Nov 9.

a Faculty of Health , Queensland University of Technology , Brisbane , Australia.

Introduction: The amyloid-beta (Aβ) cascade hypothesis is that reducing Aβ levels in the brain will be beneficial in the treatment of Alzheimer's disease. Solanezumab is a humanized analog of a murine antibody that selectively targets the central domain of the soluble form of Aβ. In the EXPEDITION 1 and 2 Phase 3 clinical trials, solanezumab was shown to be ineffective in subjects with mild-to-moderate Alzheimer's disease, and to have no effect on brain Aβ burden. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2018.1543397DOI Listing
December 2018
1 Read

The immune microenvironment in vulvar (pre)cancer: review of literature and implications for immunotherapy.

Expert Opin Biol Ther 2018 Dec 2;18(12):1223-1233. Epub 2018 Nov 2.

b Department of Gynaecology , Leiden University Medical Center , Leiden , The Netherlands.

Introduction: Vulvar squamous cell carcinoma (VSCC) develops via two different pathways: TP53 mutations in a background of lichen sclerosus or a persistent infection with high-risk human papilloma virus (HPV). The latter group of tumor responds better to treatment than the non-virally induced VSCC. This may be explained by a difference in the tumor immune microenvironment (TME). Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2018.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2018.1542426DOI Listing
December 2018
9 Reads

Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?

Expert Opin Biol Ther 2018 Dec 24;18(12):1271-1279. Epub 2018 Oct 24.

a Guy's & St. Thomas' NHS Foundation Trust , IBD Centre , London , UK.

Background: We aimed to understand the way in which therapeutic drug monitoring (TDM) is used, understood and interpreted for anti-TNF agents in IBD.

Research Design And Methods: We designed an 18-question survey that included 5 TDM-based clinical scenarios, for which the 'most appropriate' responses were based on the BRIDGe groups 'Anti-TNF Optimizer'. This resource combines TDM evidence with expert consensus. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2018.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2018.1537367DOI Listing
December 2018
5 Reads

Bimekizumab for the treatment of psoriatic disease.

Expert Opin Biol Ther 2018 Dec 23;18(12):1193-1197. Epub 2018 Oct 23.

b Department of Dermatology, New York Medical College , Metropolitan Hospital , New York , NY , USA.

Introduction: Psoriasis and psoriatic arthritis are common diseases with significant physical and emotional burden. Several biologics are FDA-approved to treat psoriasis and psoriatic arthritis, though some patients remain refractory to, or have lost response to, therapy and/or cannot tolerate the associated risks and side effects. Bimekizumab is a new biologic that inhibits both IL-17A and IL-17F. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2018.1538351DOI Listing
December 2018
2 Reads

Promise of gene therapy to treat sickle cell disease.

Expert Opin Biol Ther 2018 11 19;18(11):1123-1136. Epub 2018 Oct 19.

c Blood and Marrow Transplantation Program , UCSF Benioff Children's Hospital , Oakland , CA , USA.

Introduction: Sickle cell anemia (SCA) is a hereditary blood disease caused by a single-gene mutation that affects millions of individuals world-wide. In this review, we focus on techniques to treat SCA by ex vivo genetic manipulation of hematopoietic stem/progenitor cells (HSPC), emphasizing replacement gene therapy and gene editing. Areas covered: Viral transduction of an anti-sickling β-like globin gene has been tested in pre-clinical and early-phase clinical studies, and shows promising preliminary results. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2018.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2018.1536119DOI Listing
November 2018
10 Reads